COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

Targeting Molecular Pathway that Causes Pulmonary Arterial Hypertension

UC San Diego researchers describe imbalance of opposing cell signals that cause deadly disease, and how a novel monoclonal antibody therapy might treat or prevent it

May 06, 2022  |  

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the lungs, in which blood vessels are narrowed, blocked or destroyed, causing the heart to work harder and, in time, result in cardiac weakness and failure.

The disease is relatively rare, but affects an estimated 100,000 persons in the United States, and results in 20,000 deaths annually. There is no cure.

In a study published May 4, 2022 in Science Translational Medicine, researchers at the University of California San Diego School of Medicine describe the underlying signaling pathway that results in PAH — and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formation characterizing the disease.

Pulmonary Hypertension histograph

Evidence of pulmonary hypertension is evidence in the thickening of arterial walls. Photo credit: Wikimedia Commons

At the cellular level, PAH progresses with proliferation of vascular smooth muscle cells (vSMC) that cause small arteries in the lungs to become narrowed, leading to progressively less oxygen in the blood. A research team, led by senior author Patricia A. Thistlethwaite, MD, PhD, professor of surgery in at UC San Diego School of Medicine and a cardiothoracic surgeon at UC San Diego Health, focused on overexpression of the NOTCH ligand JAGGED-1, a binding protein involved in cell signaling and, in this case, the development of small pulmonary vSMCs.

They found that overexpression of the NOTCH3 ligand, JAGGED-1, spurs vSMC proliferation, but the NOTCH3 ligand DELTA-LIKE 4 inhibits it. The researchers then developed a therapeutic monoclonal antibody that selectively blocks JAGGED-1-induced NOTCH3 signaling, effectively reversing pulmonary hypertension in two rodent models of the disease, without toxic side effects.

“These findings reveal two opposing roles of NOTCH ligands,” said Thistlethwaite. “Importantly, it opens the door to a potentially new, safe treatment for PAH, using a monoclonal antibody that selectively inhibits NOTCH3 activation in the lung vasculature.”

Co-authors include: Yu Zhang, Moises Hernandez, Jonathan Gower, Nolan Winicki, Xena Morataya, Sebastian Alvarez, Jason X.-J. Yuan and John Shyy, all at UC San Diego.

Funding for this research came, in part, from the National Institutes of Health (grants R01HL119543 and R01HL132225).


Care at UC San Diego Health

Pulmonary Hypertension Care



Media Contact

Scott LaFee
858-249-0456
slafee@health.ucsd.edu

Share This Article


Related News

11/12/2019
National attention has been drawn to the plight of patients who have experienced the unintended side effects of prolonged ICU care such as memory loss and muscle weakness. Now, a research team led by ...
7/20/2018
The governing board of the California Institute for Regenerative Medicine unanimously approved this week two grants worth more than $2.2 million to University of California San Diego School of Medicin ...
2/26/2016
When astronaut Scott Kelly returns to Earth on March 1, half of NASA’s first-of-its-kind study of twin astronauts and long duration space flight, researchers at University of California, San Diego Sch ...
8/3/2015
Ethiopians have lived at high altitudes for thousands of years, providing a natural experiment for studying human adaptations to low oxygen, a condition known as hypoxia. One factor that may enable Et ...



Follow Us